Cargando…
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer
INTRODUCTION: The relationships among PIK3CA mutations, medication use and tumor progression remains poorly understood. Aspirin use post-diagnosis may modify components of the PI3K pathway, including AKT and mTOR, and has been associated with lower risk of breast cancer recurrence and mortality. We...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181475/ https://www.ncbi.nlm.nih.gov/pubmed/32326897 http://dx.doi.org/10.1186/s12885-020-06810-8 |
_version_ | 1783526046109270016 |
---|---|
author | McCarthy, Anne Marie Kumar, Nitya Pradeep He, Wei Regan, Susan Welch, Michaela Moy, Beverly Iafrate, A. John Chan, Andrew T. Bardia, Aditya Armstrong, Katrina |
author_facet | McCarthy, Anne Marie Kumar, Nitya Pradeep He, Wei Regan, Susan Welch, Michaela Moy, Beverly Iafrate, A. John Chan, Andrew T. Bardia, Aditya Armstrong, Katrina |
author_sort | McCarthy, Anne Marie |
collection | PubMed |
description | INTRODUCTION: The relationships among PIK3CA mutations, medication use and tumor progression remains poorly understood. Aspirin use post-diagnosis may modify components of the PI3K pathway, including AKT and mTOR, and has been associated with lower risk of breast cancer recurrence and mortality. We assessed time to metastasis (TTM) and survival with respect to aspirin use and tumor PIK3CA mutations among women with metastatic breast cancer. METHODS: Patients with hormone receptor positive, HER2 negative (HR+/HER2-) metastatic breast cancer treated in 2009–2016 who received tumor genotyping were included. Aspirin use between primary and metastatic diagnosis was extracted from electronic medical records. TTM and survival were estimated using Cox proportional hazards regression. RESULTS: Among 267 women with metastatic breast cancer, women with PIK3CA mutated tumors had longer TTM than women with PIK3CA wildtype tumors (7.1 vs. 4.7 years, p = 0.008). There was a significant interaction between PIK3CA mutations and aspirin use on TTM (p = 0.006) and survival (p = 0.026). PIK3CA mutations were associated with longer TTM among aspirin non-users (HR = 0.60 95% CI:0.44–0.82 p = 0.001) but not among aspirin users (HR = 1.57 0.86–2.84 p = 0.139). Similarly, PIK3CA mutations were associated with reduced mortality among aspirin non-users (HR = 0.70 95% CI:0.48–1.02 p = 0.066) but not among aspirin users (HR = 1.75 95% CI:0.88–3.49 p = 0.110). CONCLUSIONS: Among women who develop metastatic breast cancer, tumor PIK3CA mutations are associated with slower time to progression and mortality only among aspirin non-users. Larger studies are needed to confirm this finding and examine the relationship among aspirin use, tumor mutation profile, and the overall risk of breast cancer progression. |
format | Online Article Text |
id | pubmed-7181475 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-71814752020-04-28 Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer McCarthy, Anne Marie Kumar, Nitya Pradeep He, Wei Regan, Susan Welch, Michaela Moy, Beverly Iafrate, A. John Chan, Andrew T. Bardia, Aditya Armstrong, Katrina BMC Cancer Research Article INTRODUCTION: The relationships among PIK3CA mutations, medication use and tumor progression remains poorly understood. Aspirin use post-diagnosis may modify components of the PI3K pathway, including AKT and mTOR, and has been associated with lower risk of breast cancer recurrence and mortality. We assessed time to metastasis (TTM) and survival with respect to aspirin use and tumor PIK3CA mutations among women with metastatic breast cancer. METHODS: Patients with hormone receptor positive, HER2 negative (HR+/HER2-) metastatic breast cancer treated in 2009–2016 who received tumor genotyping were included. Aspirin use between primary and metastatic diagnosis was extracted from electronic medical records. TTM and survival were estimated using Cox proportional hazards regression. RESULTS: Among 267 women with metastatic breast cancer, women with PIK3CA mutated tumors had longer TTM than women with PIK3CA wildtype tumors (7.1 vs. 4.7 years, p = 0.008). There was a significant interaction between PIK3CA mutations and aspirin use on TTM (p = 0.006) and survival (p = 0.026). PIK3CA mutations were associated with longer TTM among aspirin non-users (HR = 0.60 95% CI:0.44–0.82 p = 0.001) but not among aspirin users (HR = 1.57 0.86–2.84 p = 0.139). Similarly, PIK3CA mutations were associated with reduced mortality among aspirin non-users (HR = 0.70 95% CI:0.48–1.02 p = 0.066) but not among aspirin users (HR = 1.75 95% CI:0.88–3.49 p = 0.110). CONCLUSIONS: Among women who develop metastatic breast cancer, tumor PIK3CA mutations are associated with slower time to progression and mortality only among aspirin non-users. Larger studies are needed to confirm this finding and examine the relationship among aspirin use, tumor mutation profile, and the overall risk of breast cancer progression. BioMed Central 2020-04-23 /pmc/articles/PMC7181475/ /pubmed/32326897 http://dx.doi.org/10.1186/s12885-020-06810-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article McCarthy, Anne Marie Kumar, Nitya Pradeep He, Wei Regan, Susan Welch, Michaela Moy, Beverly Iafrate, A. John Chan, Andrew T. Bardia, Aditya Armstrong, Katrina Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer |
title | Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer |
title_full | Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer |
title_fullStr | Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer |
title_full_unstemmed | Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer |
title_short | Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer |
title_sort | different associations of tumor pik3ca mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181475/ https://www.ncbi.nlm.nih.gov/pubmed/32326897 http://dx.doi.org/10.1186/s12885-020-06810-8 |
work_keys_str_mv | AT mccarthyannemarie differentassociationsoftumorpik3camutationsandclinicaloutcomesaccordingtoaspirinuseamongwomenwithmetastatichormonereceptorpositivebreastcancer AT kumarnityapradeep differentassociationsoftumorpik3camutationsandclinicaloutcomesaccordingtoaspirinuseamongwomenwithmetastatichormonereceptorpositivebreastcancer AT hewei differentassociationsoftumorpik3camutationsandclinicaloutcomesaccordingtoaspirinuseamongwomenwithmetastatichormonereceptorpositivebreastcancer AT regansusan differentassociationsoftumorpik3camutationsandclinicaloutcomesaccordingtoaspirinuseamongwomenwithmetastatichormonereceptorpositivebreastcancer AT welchmichaela differentassociationsoftumorpik3camutationsandclinicaloutcomesaccordingtoaspirinuseamongwomenwithmetastatichormonereceptorpositivebreastcancer AT moybeverly differentassociationsoftumorpik3camutationsandclinicaloutcomesaccordingtoaspirinuseamongwomenwithmetastatichormonereceptorpositivebreastcancer AT iafrateajohn differentassociationsoftumorpik3camutationsandclinicaloutcomesaccordingtoaspirinuseamongwomenwithmetastatichormonereceptorpositivebreastcancer AT chanandrewt differentassociationsoftumorpik3camutationsandclinicaloutcomesaccordingtoaspirinuseamongwomenwithmetastatichormonereceptorpositivebreastcancer AT bardiaaditya differentassociationsoftumorpik3camutationsandclinicaloutcomesaccordingtoaspirinuseamongwomenwithmetastatichormonereceptorpositivebreastcancer AT armstrongkatrina differentassociationsoftumorpik3camutationsandclinicaloutcomesaccordingtoaspirinuseamongwomenwithmetastatichormonereceptorpositivebreastcancer |